Paeds Vivas · gastroenterology-hepatology-and-nutrition
Gastro-oesophageal reflux and reflux disease — structured oral (viva)
Branching structured oral on an unsettled thriving infant with posseting, testing the distinction between physiologic reflux and disease, the conservative-first ladder, exclusion of cow's milk protein allergy, and the evidence against acid suppression.
On this page
Study tools
Target exams
Branch 1 — Definition and classification
Examiner: "Is this reflux or GORD, and what separates the two?" Candidate: This is physiologic gastro-oesophageal reflux. GOR is the effortless retrograde passage of gastric contents into the oesophagus, and in infants it is a normal, self-limiting developmental phenomenon. GORD is reserved for reflux that causes troublesome symptoms or complications — faltering growth, oesophagitis, haematemesis, recurrent aspiration, or distress impairing quality of life. This infant is thriving with effortless posseting and no red flags, so this is physiologic reflux, not disease. [1]
Examiner: "What red flags would change your mind?" Candidate: I would reconsider with bilious or green vomiting, forceful or projectile vomiting, faltering growth, haematemesis or anaemia, or recurrent aspiration. Late onset after six months or persistence beyond the first birthday would also make me look for another diagnosis. Bilious vomiting is the cardinal danger sign — it signals intestinal obstruction, most dangerously malrotation with volvulus, and it needs urgent contrast imaging and surgical review, not anti-reflux therapy. [1]
References3ShowHide
- [1]Rosen R, Vandenplas Y, Singendonk M, et al Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr, 2018.PMID 29470322
- [2]Orenstein SR, Hassall E, Furmaga-Jablonska W, et al Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr, 2009.PMID 19054529
- [3]Puoti MG, Assa A, Benninga M, et al Drugs in Focus: Domperidone. J Pediatr Gastroenterol Nutr, 2023.PMID 37159421